Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Other Non-Current Assets came in at $1.8 billion in Q2 2026, down 2.61% YoY from $1.8 billion in Q2 2025, and little changed on a QoQ basis from $1.8 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Other Non-Current Assets data on file, last reported at $1.8 billion in Q2 2026.
- Quarterly Other Non-Current Assets fell 2.61% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (down 2.61% YoY) and the FY2025 annual result came in at $1.8 billion, up 4.01% from the prior year.
- Other Non-Current Assets steadied at $1.8 billion in Q2 2026, from $1.8 billion in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.8 billion in Q2 2025 to a low of $434.0 million in Q2 2024.
- A 5-year average of $981.9 million and a median of $471.0 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets retreated 15.44% — and 2025, when it soared 324.42%.
- Tracing TEVA's Other Non-Current Assets over 5 years: stood at $441.0 million in 2022, then gained by 6.58% to $470.0 million in 2023, then soared by 276.81% to $1.8 billion in 2024, then advanced by 4.01% to $1.8 billion in 2025, then dropped by 2.61% to $1.8 billion in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Bn |
| Mar 31, 2026 | 1.79 Bn |
| Dec 31, 2025 | 1.84 Bn |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | 1.84 Bn |
| Mar 31, 2025 | 1.81 Bn |
| Dec 31, 2024 | 1.77 Bn |
| Sep 30, 2024 | 459.00 Mn |
| Jun 30, 2024 | 434.00 Mn |
| Mar 31, 2024 | 470.00 Mn |
| Dec 31, 2023 | 470.00 Mn |
| Sep 30, 2023 | 477.00 Mn |
| Jun 30, 2023 | 443.00 Mn |
| Mar 31, 2023 | 450.00 Mn |
| Dec 31, 2022 | 441.00 Mn |
| Sep 30, 2022 | 438.00 Mn |
| Jun 30, 2022 | 454.00 Mn |
| Mar 31, 2022 | 472.00 Mn |
| Dec 31, 2021 | 515.00 Mn |
| Sep 30, 2021 | 518.00 Mn |